MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mo, Y.-Y.
Right arrow Articles by Beck, W. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mo, Y.-Y.
Right arrow Articles by Beck, W. T.

Vol. 55, Issue 2, 216-222, February 1999

DNA Damage Signals Induction of Fas Ligand in Tumor Cells

Yin-Yuan Mo and William T. Beck

Division of Developmental Therapeutics, Cancer Center, University of Illinois at Chicago, Chicago, Illinois

Many anticancer agents exert their cytotoxicity through DNA damage and induction of apoptosis. Fas ligand (FasL), a key component of T lymphocytes, has been shown to be induced by some of those agents. To address what is an early signal for this induction, we constructed a FasL promoter-luciferase reporter gene to investigate effects of DNA topoisomerase (Topo) II inhibitors on FasL promoter activity. Transient transfection assays in HeLa and other tumor cell lines demonstrated that induction of FasL promoter activity in response to Topo II inhibitors such as VM-26 mimicked endogenous FasL expression under the same conditions. The ability of these agents to induce FasL expression correlated with their ability to cause DNA damage. For instance, complex-stabilizing Topo II inhibitors such as etoposide, teniposide, and doxorubicin, which cause DNA damage, strongly induce FasL expression; by contrast, non-DNA-damaging catalytic Topo II inhibitors such as ICRF-187 and merbarone do not do this. In support of the notion that DNA damage triggers FasL induction, we found that DNA-damaging irradiation also induced FasL promoter activity in a dose-dependent manner. Finally, the catalytic Topo II inhibitor ICRF-187 suppressed VM-26-induced-FasL expression. This suppression correlated with the ability of this drug to inhibit VM-26-induced DNA strand breaks. Together, our results suggest that DNA damage in response to agents such as etoposide and teniposide might serve as an early signal to induce FasL expression.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
T. J. Page, S. O'Brien, C. R. Jefcoate, and C. J. Czuprynski
7,12-Dimethylbenz[a]anthracene Induces Apoptosis in Murine Pre-B Cells through a Caspase-8-Dependent Pathway
Mol. Pharmacol., August 1, 2002; 62(2): 313 - 319.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Herr and K.-M. Debatin
Cellular stress response and apoptosis in cancer therapy
Blood, November 1, 2001; 98(9): 2603 - 2614.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J.-H. Lai, L.-J. Ho, K.-C. Lu, D.-M. Chang, M.-F. Shaio, and S.-H. Han
Western and Chinese Antirheumatic Drug-Induced T Cell Apoptotic DNA Damage Uses Different Caspase Cascades and Is Independent of Fas/Fas Ligand Interaction
J. Immunol., June 1, 2001; 166(11): 6914 - 6924.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Bellarosa, A. Ciucci, A. Bullo, F. Nardelli, S. Manzini, C. A. Maggi, and C. Goso
Apoptotic Events in a Human Ovarian Cancer Cell Line Exposed to Anthracyclines
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 276 - 283.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. Mandlekar, V. Hebbar, K. Christov, and A-N. T. Kong
Pharmacodynamics of Tamoxifen and Its 4-Hydroxy and N-Desmethyl Metabolites: Activation of Caspases and Induction of Apoptosis in Rat Mammary Tumors and in Human Breast Cancer Cell Lines
Cancer Res., December 1, 2000; 60(23): 6601 - 6606.
[Abstract] [Full Text]

Home page
 BloodHome page
A. P. Bruno, D. Lautier, A. d. T. d'Orgeix, G. Laurent, and A. Quillet-Mary
Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin
Blood, September 1, 2000; 96(5): 1914 - 1920.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. B. Gibson, R. Oyer, A. C. Spalding, S. M. Anderson, and G. L. Johnson
Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL
Mol. Cell. Biol., January 1, 2000; 20(1): 205 - 212.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
T. Khélifa and W. T. Beck
Merbarone, a Catalytic Inhibitor of DNA Topoisomerase II, Induces Apoptosis in CEM Cells through Activation of ICE/CED-3-like Protease
Mol. Pharmacol., March 1, 1999; 55(3): 548 - 556.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
M. P. Boland, K. A. Fitzgerald, and L. A. J. O'Neill
Topoisomerase II Is Required for Mitoxantrone to Signal Nuclear Factor kappa B Activation in HL60 Cells
J. Biol. Chem., August 11, 2000; 275(33): 25231 - 25238.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics